An observational study in Transplant-Related Disorder, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational
This study collects immune reconstitution data of umbilical cord blood transplant recipients at multiple time points after transplantation to explore the characteristics and relevant influencing factors of immune reconstitution.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 412 studies on the registry; 291 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients receiving umbilical cord blood transplant
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The quantity and diversity of immune cells
The quantity and diversity of immune cells such as T cells, B cells, and NK cells within one year after transplantation in the overall patients, adult patients, and pediatric patients.
Time frame: On post-transplant days 30 ± 3, 60 ± 3, 90 ± 3, 120 ± 3, 180 ± 7, 270 ± 7, and 360 ± 7
Incidence of engraftment syndrome
Incidence of engraftment syndrome in the overall patients, adult patients, and pediatric patients
Time frame: 1 year post-transplant
Incidence of infections
Incidence of engraftment syndrome in the overall patients, adult patients, and pediatric patients
Time frame: 1 year post-transplant
Incidence of relapse
Incidence of engraftment syndrome in the overall patients, adult patients, and pediatric patients
Time frame: 1 year post-transplant
Incidence of non-relapse mortality
Incidence of engraftment syndrome in the overall patients, adult patients, and pediatric patients
Time frame: 1 year post-transplant
Incidence of graft-versus-host disease
Incidence of engraftment syndrome in the overall patients, adult patients, and pediatric patients
Time frame: 1 year post-transplant
survival
Incidence of engraftment syndrome in the overall patients, adult patients, and pediatric patients
Time frame: 1 year post-transplant
Started Oct 2026 (actual). Primary completion is estimated for May 2028, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Hematology & Blood Diseases Hospital, China →